The drug may be eligible for the Innovative Licensing and Access Pathway (ILAP), which aims to accelerate the time to market for innovative medicines that address significant public health needs
Product amount: 29.77 oz./844g
However, study results for some are sparse, or have not been published in scientific journals
Limitations of the therapeutic use of superoxide dismutase Due to the instability, high immunogenicity, low cellular uptake and less in vivo circulation of the half-life of superoxide dismutase, their clinical use as therapeutic agents is very limited
Many patients, such as heart disease, hyperlipidemia, kidney disease, liver cirrhosis, malnutrition, hypothyroidism and some muscle and neurological diseases, generally have low carnitine levels